Trial Design
Adaptive Trial Design
An adaptive trial design is a clinical trial that uses pre-specified rules to modify aspects of the study (sample size, randomization ratio, dose, treatment arms, endpoints) based on accumulating interim data, without compromising scientific validity.
Adaptive designs are governed by FDA's 2019 guidance Adaptive Designs for Clinical Trials of Drugs and Biologics. Common adaptations include sample-size re-estimation, group-sequential boundaries, response-adaptive randomization, dose-finding (e.g., CRM, BOIN), and seamless Phase 2/3 transitions.
Adaptive trials can shorten development timelines by 12; 24 months in oncology and rare disease, but require detailed simulation, blinded data review committees, and pre-specified statistical analysis plans to avoid Type 1 error inflation.
References
Related terms
Clinical Trial Phases
Clinical trial phases are the sequential stages of human drug testing; Phase 1 evaluates safety in small healthy or patient cohorts, Phase 2 tests efficacy and dose in target patients, Phase 3 confirms efficacy and safety at scale to support marketing approval, and Phase 4 monitors long-term outcomes after approval.
Statistical Analysis Plan (SAP)
A Statistical Analysis Plan (SAP) is a detailed technical document that specifies, before database lock, every statistical analysis to be performed on a clinical trial's data, including primary and secondary endpoint analyses, handling of missing data, multiplicity adjustments, and sensitivity analyses.
Endpoint (Clinical Trial)
A clinical trial endpoint is a defined, measurable outcome that determines whether the intervention being studied has the intended effect; it is the variable on which the trial's success or failure is statistically evaluated.
Platform Trial
A platform trial is a clinical trial that evaluates multiple investigational treatments against a common control under a single master protocol, with treatments added or dropped over time based on accumulating evidence.
See how Kitsa applies this in your trials
Kitsa's agentic AI compresses protocol development, site selection, and patient pre-screening from months into weeks.
Request a demo